There is great geographical variation in the distribution of hepatocellular carcinoma (HCC),
with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one …

Introduction The treatment algorithm of advanced hepatocellular carcinoma (HCC) has
evolved since the introduction of immunotherapy. The IMbrave150 trial set atezolizumab …

PURPOSE Lenvatinib (LEN) is a first-line therapy for patients with advanced hepatocellular
carcinoma (HCC); however, it has shown modest survival benefits. Therefore, we aimed to …

Purpose This open-label phase III trial evaluated efficacy and tolerability of linifanib versus
sorafenib in patients with advanced hepatocellular carcinoma (HCC) without prior systemic …

EASL–EORTC Clinical Practice Guidelines (CPG) on the management of hepatocellular
carcinoma (HCC) define the use of surveillance, diagnosis, and therapeutic strategies …

Background & Aims Overall survival (OS) is a composite clinical endpoint in hepatocellular
carcinoma (HCC) due to the mutual influence of cirrhosis and active malignancy in dictating …

Liver cancer is the fourth most prevalent and the second most lethal cancer in China.
Hepatitis B virus (HBV) infection represents a major risk factor for hepatocellular carcinoma …

To clarify the significance of circulating tumor cells (CTC) undergoing epithelial–
mesenchymal transition (EMT) in patients with hepatocellular carcinoma (HCC), we used an …

BACKGROUND & AIMS: The Sorafenib Hepatocellular Carcinoma (HCC) Assessment
Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall survival …

EASL–EORTC Clinical Practice Guidelines (CPG) on the management of hepatocellular
carcinoma (HCC) define the use of surveillance, diagnosis, and therapeutic strategies …